drug-discovery-biochemistry-conference-2017-posters

25 / 27

Page 81
allied
academies
J Pharmacol Ther Res 2017 Volume 1 Issue 2
November 02-03, 2017 Chicago, USA
4 th International Congress on
International Conference and Exhibition on
Drug Discovery, Designing and Development
Biochemistry, Molecular Biology: R&D
&
Most recently approved oncology drugs target discrete
molecular aberrations or pathways in tumor cells
and consequently are active on a subset of the patient
population. The problemmainly lies in the vast heterogeneity
that exists between tumor types, individuals with the same
type of tumor, and within one tumor of a patient at any given
time. The Predictive biomarkers, measured using in vitro
companion diagnostics (IVD), help identify patients likely to
respond to treatment and are increasingly integrated into
drug development programs. This presentation will provide
an update of biomarker-directed oncology drugs approved
by the US Food and Drug Administration. Case studies will be
presented on therapeutic monoclonal antibodies selectively
targeting HER2, EGFR, or PD-1/PD-L1 signaling pathways.
This information will be further discussed with respect to
biomarker qualification in the development of novel cancer
therapeutics.
e:
Biomarker-directed drug development in oncology-20 years and counting
Baolin Zhang
Food and Drug Administration, USA